Duloxetine use in painful conditions

Bibliography

• Miller A, Rabe-Jablonska J. The effectiveness of antidepressants in the treatment of chronic non-cancer pain – a review. Psychiatr Pol 2005;39:21-32
   PubMedGoogle Scholar
• Atkinson JH, Patel SM, Meyer JM, Is there a therapeutic window with some antidepressants for analgesic response? Curr Pain Headache Rep 2009;13:93-9
   PubMed Web of Science ®Google Scholar
• Jus A, Bujalska M, Makulska-Nowak HE. Modification of fentanyl analgesia by antidepressants. Pharmacology 2010;85:48-53
   Google Scholar
• Tomic MA, Vuckovic SM, Stepanovic-Petrovic RM, Analysis of the antinociceptive interactions in two-drug combinations of gabapentin, oxcarbazepine and amitriptyline in streptozotocin-induced diabetic mice. Eur J Pharmacol 2010;628:75-82
   Google Scholar
• Goldstein FJ. Adjunct to opioid therapy. J Am Osteopath Assoc 2002;102(Suppl 3):S15-21
   Google Scholar
• Barkin RL, Fawcett J. The management challenges of chronic pain: the role of antidepressants. Am J Ther 2000;7:31-47
   Google Scholar
• Bajwa ZH, Simopoulos TT, Pal J, Low and therapeutic doses of antidepressants are associated with similar response in the context of multimodal treatment of pain. Pain Physician 2009;12:893-900
   Google Scholar
• Brannan SK, Mallinckrodt CH, Brown EB, Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005;39:43-53
   PubMed Web of Science ®Google Scholar
• Jones CK, Peters SC, Shannon HE. Efficacy of duloxetine, a potent and balanced serotonergic and noradrenergic reuptake inhibitor, in inflammatory and acute pain models in rodents. J Pharmacol Exp Ther 2005;312:726-32
   PubMed Web of Science ®Google Scholar
• Jones CK, Peters SC, Shannon HE. Synergistic interactions between the dual serotonergic, noradrenergic reuptake inhibitor duloxetine and the non-steroidal anti-inflammatory drug ibuprofen in inflammatory pain in rodents. Eur J Pain 2007;11:208-15
   PubMed Web of Science ®Google Scholar
• Pettersen VL, Zapata-Sudo G, Raimundo JM, The synergistic interaction between morphine and maprotiline after intrathecal injection in rats. Anesth Analg 2009;109:1312-17
   PubMed Web of Science ®Google Scholar
• Ho KY, Tay W, Yeo MC, Duloxetine reduces morphine requirements after knee replacement surgery. Br J Anaesth 2010;105:371-6
   PubMed Web of Science ®Google Scholar
• Namaka M, Leong C, Grossberndt A, A treatment algorithm for neuropathic pain: an update. Consult Pharm 2009;24:885-902
   Google Scholar
• Attal N, Cruccu G, Baron R, EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-23
   PubMed Web of Science ®Google Scholar
• Arnold LM, Lu Y, Crofford LJ, A double-blind, multicenter trial comparing duloxetine with placebo in the treatmen tof fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004;50:2974-84
   PubMed Web of Science ®Google Scholar
• Arnold LM, Rosen A, Pritchett YL, A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005;119:5-15
   PubMed Web of Science ®Google Scholar
• Russell IJ, Mease PJ, Smith TR, Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain 2008;136:432-44
   PubMed Web of Science ®Google Scholar
• Chappell AS, Bradley LA, Wiltse C, A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia. Int J Gen Med 2009;1:91-102
   Google Scholar
• Hauser W, Petzke F, Uceyler N, Sommer C. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology 2011;50:532-43
   PubMed Web of Science ®Google Scholar
• Marangell LB, Clauw DJ, Choy E, Comparative pain and mood effects in patients with comorbid fibromyalgia and major depressive disorder: secondary analyses of four pooled randomized controlled trials of duloxetine. Pain 2011;152:31-7
   PubMed Web of Science ®Google Scholar
• Raskin J, Pritcherr YL, Wang F, A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005;6:346-56
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005;116:109-18
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Pritchett YL, D'Souza DN, A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology 2006;67:1411-20
   PubMed Web of Science ®Google Scholar
• Gao Y, Ning G, Jia WP, Duloextine versus placebo in the treatment of patients with diabetic neuropathic pain in China. Chin Med J 2010;123:3184-92
   PubMed Web of Science ®Google Scholar
• Kajdasz DK, Iyengar S, Desaiah D, Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. Clin Ther 2007;29(Suppl):2536-46
   Google Scholar
• Hall JA, Wang F, Oakes TM, Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials. Expert Opin Drug Saf 2010;9:525-37
   PubMed Web of Science ®Google Scholar
• Vranken JH, Hollmann MW, van der Vegt MH, Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial. Pain 2011;152:267-73
   PubMed Web of Science ®Google Scholar
• Mignogna MD, Adamo D, Schiavone V, Burning mouth syndrome responsive to duloxetine: a case report. Pain Med 2011;12:466-9
   Google Scholar
• Farrar JT, Young JP, LaMoreaux L, Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149-58
   PubMed Web of Science ®Google Scholar
• Farrar JT, Pritchett YL, Robinson M, The clinical importance of changes in the 0 to 10 numeric rating scale for worst, least, and average pain intensity: analyses of data from clinical trials of duloxetine in pain disorders. J Pain 2010;11:109-18
   PubMed Web of Science ®Google Scholar
• Salaffi F, Stancati A, Silvestri CA, Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain 2004;8:283-91
   PubMed Web of Science ®Google Scholar
• Hoffman DL, Sadosky A, Dukes EM, Alvir J. How do changes in pain severity levels correspond to changes in health status and function in patients with painful diabetic peripheral neuropathy? Pain 2010;149:194-201
   PubMed Web of Science ®Google Scholar
• Chandran P, Pai M, Blomme EA, Pharmacological modulation of movement-evoked pain in a rat model of osteoarthritis. Eur J Pharmacol 2009;613:39-45
   Google Scholar
• Sullivan MD, Bentley S, Fan MY, Gardner G. A single-blind, placebo run-in study of duloxetine for activity-limiting osteoarthritis pain. J Pain 2009;10:208-13
   PubMed Web of Science ®Google Scholar
• Chappell AS, Ossanna MJ, Liu-Seifert H, Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: a 13-week, randomized, placebo-controlled trial. Pain 2009;146:253-60
   PubMed Web of Science ®Google Scholar
• Chappell AS, Desaiah D, Liu-Seifert H, A double-blind, randomized, placebo-controlled study of the efficacy and safety of duloxetine for the treatment of chronic pain due to osteoarthritis of the knee. Pain Pract 2011;11:33-41
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Ossanna M, Liu-Seifert H, A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol 2009;16:1041-8
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Zhang S, Desaiah D, Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain 2010;11:1282-90
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Zhang S, Chappell AS, Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study. Pain Med 2010;11:648-57
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Desaiah D, Liu-Seifert H, Efficacy and safety of duloxetine in patients with chronic low back pain. Spine 2010c;35:E578-85
   Web of Science ®Google Scholar
• Mazza M, Mazza O, Pazzaglia C, Escitalopram 20 mg versus duloxetine 60 mg for the treatment of chronic low back pain. Expert Opin Pharmacother 2010;11:1049-52
   PubMed Web of Science ®Google Scholar
• Brunton S, Wang F, Edwards SB, Profile of adverse events with duloxetine treatment: a pooled analysis of placebo-controlled studies. Drug Saf 2010;33:393-407
   PubMed Web of Science ®Google Scholar
• Jensen MP, Smith DG, Ehde DM, Robinson LR. Pain site and the effects of amputation pain: further clarifying the meaning of mild, moderate, and severe pain. Pain 2001;91:317-22
   PubMed Web of Science ®Google Scholar
• Zelman DC, Dukes E, Brandenburg N, Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. Pain 2005;115:29-36
   PubMed Web of Science ®Google Scholar
• Paul SM, Zelman DC, Smith M, Miaskowski C. Categorizing the severity of cancer pain: further exploration of the establishment of cutpoints. Pain 2005;113:37-44
   PubMed Web of Science ®Google Scholar
• Serlin RC, Mendoza TR, Nakamura Y, When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995;61:277-84
   PubMed Web of Science ®Google Scholar
• Li KK, Harris K, Hadi S, Chow E. What should be the optimal cut points for mild, moderate, and severe pain? J Palliat Med 2007;10:1338-46
   PubMed Web of Science ®Google Scholar
• Given B, Given CW, Sikorskii A, Establishing mild, moderate and severe scored for cancer-related symptoms: how consistent and clinically meaningful are interference-based severity cut-points? J Pain Symptom Manage 2008;35:126-35
   PubMed Web of Science ®Google Scholar
• Scascighini L, Toma V, Dober-Spielmann S, Sprott H. Multidisciplinary treatment for chronic pain: a systematic review of interventions and outcomes. Rheumatology 2008;47:670-8
   PubMed Web of Science ®Google Scholar